SleepWell Trade

Trend-Following Backtester · Guide · backtest 한국어

equity · US

Akebia Therapeutics, Inc. backtest

10 trend-following strategies were compared on the full daily history of Akebia Therapeutics, Inc.. 10 beat buy-and-hold CAGR; MACD ranks first by Sharpe, matching the main backtester. The return/drawdown alternative is ADX / DI 방향성 (CAGR 2.2%, MDD -34.8%).

Data 2014-03-20 ~ 2026-07-31daily bars 3,110 (12.4 years)Costs 0.5%Venue XNASMonthly snapshot 2026-07-31

Results by strategy

10 of 10 beat buy and hold (CAGR -21.6%, drawdown -99.1%).

Sharpe leader (same as main): MACD — CAGR 10.2%, MDD -71.5%, Sharpe 0.45, 52% exposure.

Return/drawdown alternative: ADX / DI 방향성 — CAGR is 31.8%p higher than buy and hold, while drawdown improves by 27.6%p (CAGR 2.2%, MDD -34.8%, exposure 6%).

The alternative must retain 75% of buy-and-hold CAGR, improve drawdown by at least 20% and 5 percentage points, and stay below 95% exposure; the ranking weights return retention 60% and drawdown improvement 40%.

Strategy · parametersCAGRMDDSharpeCalmarTotalTradesExposure
MACD
fast=18, slow=28, signal=15
10.2%-71.5%0.450.143.3x13852%
SMA 크로스오버
fast=86, slow=98
1.9%-87.0%0.370.021.3x5445%
Supertrend
period=8, mult=1.8
3.7%-74.3%0.330.051.6x15742%
ROC 모멘텀
n=127, threshold=0.06
3.1%-68.4%0.320.051.5x10040%
볼린저 밴드 돌파
n=17, k=1.3
2.8%-76.6%0.300.041.4x17833%
Donchian 채널 돌파
entryN=116, exitN=91
-3.4%-82.0%0.25-0.040.7x1034%
EMA 크로스오버
fast=55, slow=130
-3.8%-84.1%0.25-0.040.6x1435%
Parabolic SAR
step=0.015, maxStep=0.18
-0.9%-80.3%0.25-0.010.9x20243%
ADX / DI 방향성
period=20, threshold=33
2.2%-34.8%0.210.061.3x186%
Keltner 채널 돌파
emaPeriod=22, atrPeriod=28, mult=2.2
-3.1%-56.6%0.08-0.050.7x6017%
Buy and hold-21.6%-99.1%0.18-0.220.0x1100%
0.01 0.1 1x 2015 2017 2019 2021 2023 2025 MACDBuy and hold
MACD: Solid strategy line versus dashed buy-and-hold line. Log scale.
0% -25% -50% -74% -99% 2015 2017 2019 2021 2023 2025 Buy and holdMACD
MACD maximum drawdown -71.5% (2017-09-29 → 2019-10-25), recovered after 1,365 days.

Rules of the top strategy

Looks at the gap (MACD) between a short and long average crossing its own signal line.

Method and caveats

Past performance does not guarantee future returns. Parameters were selected on the same full-history sample using sharpe over 40 trials per strategy, so results contain in-sample bias. 0.5% trading costs are included; taxes, slippage and rejected orders are not.
Re-run the same setupMore US assetsAll asset reports

Read next